FTC Wants To Help Generic Companies Seek Declaratory Judgments On Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Language in the Medicare Rx law encouraging declaratory judgment proceedings is "woolly," FTC Commissioner Leary tells GPhA. The mechanism may be hampered by "strategic behavior" by brand firms.
You may also be interested in...
Zoloft Patent Dispute: FTC Wants Teva’s Declaratory Judgment Case Against Pfizer Restored
The case could create “the first appellate precedent regarding whether there is a justiciable ‘controversy’” when a subsequent ANDA filer sues a brand manufacturer for a declaratory judgment on noninfringement, the commission says in an amicus brief in support of Teva.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.